Abiopharma

🔍 Ralston Dianne B. (Executive)

Company: SLB LIMITED/NV (SLB)

Report Date: 2026-03-13

Detailed Transactions and Holdings:

• Acquired 3,203 shares of Common Stock, $0.01 Par Value Per Share (Direct)
  Date: 2026-03-13 | Code: A | equity_swap_involved: 0 | shares_owned_after: 227,300.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,261 shares of Common Stock, $0.01 Par Value Per Share at $44.22 per share (Direct)
  Date: 2026-03-13 | Code: F | equity_swap_involved: 0 | shares_owned_after: 226,039.00 | transaction_form_type: 4

Footnotes:

• F1: The Company granted performance share units ("PSUs") to the reporting person on January 18, 2023. Vesting of the PSUs was based on three-year Company performance relative to select key competitors. Most of these competitors had not reported their 2025 audited financial results when the Company's compensation committee met in January 2026 to certify performance under the PSUs. As a result, the Company's compensation committee approved the issuance of 80% of the shares that the committee determined had been earned according to the information available to the committee at the time. As of March 13, 2026, all such competitors had reported their 2025 audited financial results. Shares of common stock reported hereunder represent shares finally determined to have been earned under the PSUs.